Needham & Co Upgrades Cepheid (CPHD) to Buy
CPHD Hot Sheet
Rating Summary:9 Buy, 3 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 1
Needham & Co upgrades Cepheid (Nasdaq: CPHD) from Hold to Buy. Price target $17.
To see more analyst ratings on CPHD Click Here.
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for genetic testing in the clinical molecular diagnostic, industrial, and biothreat markets.
To see more analyst ratings on CPHD Click Here.
Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for genetic testing in the clinical molecular diagnostic, industrial, and biothreat markets.
You May Also Be Interested In
- UPDATE: UBS Upgrades Assured Guaranty (AGO) to Buy; Opportunity Opens After Recent Dip on Moody's Review
- Goldman Sachs Upgrades Northrop Grumman (NOC) to Neutral; Coming Back Onto Radar Screens
- Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
Create E-mail Alert Related Categories
UpgradesRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
